Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease

Journal of the National Cancer Institute

Volumn 94, Issue 3, 2002, Pages 182-192

  Travis, Lois B ^a,m   Gospodarowicz, Mary ^b   Curtis, Rochelle E ^a   Clarke, E Aileen ^c   Andersson, Michael ^d   Glimelius, Bengt ^e   Joensuu, Timo ^f   Lynch, Charles F ^g   Van Leeuwen, Flora E ^h   Holowaty, Eric ^c   Storm, Hans ^d   Glimelius, Ingrid ^e   Pukkala, Eero ⁱ   Stovall, Marilyn ^j   Fraumeni Jr , Joseph F ^a   Boice Jr , John D ^k,l   Gilbert, Ethel ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c CANCER CARE ONTARIO   (Canada)

^d DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^e UPPSALA UNIVERSITY   (Sweden)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g UNIVERSITY OF IOWA   (United States)

^h NETHERLANDS CANCER INSTITUTE   (Netherlands)

ⁱ FINNISH CANCER REGISTRY   (Finland)

^j UNIVERSITY OF TEXAS   (United States)

^k INTERNATIONAL EPIDEMIOLOGY INSTITUTE   (United States)

^l VANDERBILT INGRAM CANCER CENTER   (United States)

^m NATIONAL INSTITUTES OF HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BLEOMYCIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DOXORUBICIN; LOMUSTINE; NITROSOUREA; PREDNISONE; PROCARBAZINE; THIOTEPA; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CAUSE OF DEATH; CIGARETTE SMOKING; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HODGKIN DISEASE; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION DOSE; RISK ASSESSMENT; SCHOOL CHILD; TUMOR LOCALIZATION;

EID: 0037028736     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.3.182     Document Type: Article

References (54)

1. Second cancer after the treatment for Hodgkin's disease: A report from the international database on Hodgkin's disease
2. Second cancer risk following Hodgkin's disease: A 20-year follow-up study
3. Hodgkin's disease: Complications of therapy and excess mortality
4. Lung cancer following Hodgkin's disease: A case-control study
5. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease
6. Lung cancer after Hodgkin's disease: A nested case-control study of the relation to treatment
7. Cancer incidence in five continents
8. Risk of leukemia following platinum-based chemotherapy for ovarian cancer
9. Lung cancer after Hodgkin's disease
10. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: The relation to age at treatment
11. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma
12. Treatment-associated leukemia following testicular cancer
13. Tissue doses from radiotherapy of cancer of the uterine cervix
14. Fetal dose from radiotherapy with photon beams: Report of AAPM Radiation Therapy Committee Task Group No. 36
15. Statistical methods in cancer research. Volume I. The analysis of case-control studies
16. Ionizing radiation
17. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Overall evaluation of carcinogenicity: An updating of IARC Monographs
18. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre
19. Combination chemotherapy in the treatment of advanced Hodgkin's disease
20. International Classification of Diseases for Oncology
21. Cancers of the lung and pleura
22. Antitumor alkylating agents
23. 6 position of guanine in DNA is the most likely initiating event in carcinogenesis by methylating agents
24. Tobacco smoke carcinogens and lung cancer
25. 6-methylguanine in human blood leukocyte DNA during exposure to procarbazine and its relationships with dose and repair
26. 6-methylguanine repair in fibroblast cultures from patients with lung cancer
27. 6-alkylguanine DNA alkyltransferase gene in lung cancer risk
28. Predicting lung cancer by detecting aberrant promoter methylation in sputum
29. 6-methylguanine
30. Immunomodulatory effects of cigarette smoke
31. Drug interactions with tobacco smoking. An update
32. Reactive chemicals and cancer
33. Lung cancer risk and radiation dose among women treated for breast cancer
34. Treatment of early-stage Hodgkin's disease
35. Risk of second cancers after treatment for Hodgkin's disease
36. Genomic instability and recurrent breakpoints are main cytogenetic findings in Hodgkin's disease
37. Molecular changes in second primary lung and breast cancers after therapy for Hodgkin's disease
38. Second cancers in patients with chronic lymphocytic leukemia
39. Second cancers among long-term survivors of non-Hodgkin's lymphoma
40. Cancer risk after renal transplantation in the Nordic countries, 1964-1986
41. Radiation-associated lung cancer: A comparison of the histology of lung cancers in uranium miners and survivors of the atomic bombings of Hiroshima and Nagasaki
42. Lung cancer in radon-exposed miners and estimation of risk from indoor exposure
43. Molecular biology overview
44. Tobacco
45. Leukemia risk following Hodgkin's disease: Relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage
46. The role of radiotherapy for early stage Hodgkin's disease: Limitations and perspectives
47. Second cancers
48. A study of survivals in Hodgkin's disease treated radiologically
49. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
50. Hodgkin's disease
51. Hodgkin's disease